Inovio Pharmaceuticals (INO) Assets Average (2011 - 2026)

Inovio Pharmaceuticals has disclosed Assets Average across 16 years of filings, most recently posting $49.6 million for Q2 2026.

• In Q2 2026, Assets Average fell 36.23% year-over-year to $49.6 million; the TTM figure through Jun 2026 stood at $49.6 million (down 36.23% YoY), while the FY2025 annual figure was $93.8 million, down 34.01% from the prior year.
• Assets Average came in at $49.6 million for Q2 2026 at Inovio Pharmaceuticals, down from $62.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $470.7 million in Q1 2022 to a low of $49.6 million in Q2 2026.
• Average Assets Average over 5 years is $200.8 million, with a median of $140.7 million recorded in 2024.
• Year-over-year, Assets Average retreated 21.19% in 2022 and plunged 51.22% in 2024.
• Over 5 years, Assets Average stood at $370.3 million in 2022, then tumbled by 50.84% to $182.0 million in 2023, then slumped by 39.5% to $110.1 million in 2024, then sank by 34.76% to $71.8 million in 2025, then tumbled by 30.99% to $49.6 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $49.6 million in Q2 2026, $62.0 million in Q1 2026, and $71.8 million in Q4 2025.